Abbott Laboratories $ABT Stake Cut by Glenmede Trust Co. NA

Key Points

• Glenmede Trust reduced its Abbott Laboratories stake by 5.7% in the first quarter, selling 65,035 shares and retaining 1,069,850 shares valued at approximately $109.8 million. Institutional investors collectively own 75.18% of Abbott.
• Abbott exceeded quarterly expectations with EPS of $1.31 and revenue of $12.59 billion, while revenue increased 13% year over year. The company issued full-year 2026 EPS guidance of $5.45–$5.60.
• Abbott declared a quarterly dividend of $0.63 per share, equal to an annualized $2.52 and a 2.4% yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $118.17, despite several recent target-price cuts.

Glenmede Trust Co. NA cut its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 5.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,069,850 shares of the healthcare product maker's stock after selling 65,035 shares during the quarter. Glenmede Trust Co. NA owned 0.06% of Abbott Laboratories worth $109,841,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in ABT. Freemont Management S.A. raised its stake in shares of Abbott Laboratories by 197.2% during the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker's stock worth $1,341,000 after purchasing an additional 7,100 shares in the last quarter. PFA Pension Forsikringsaktieselskab bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at approximately $116,580,000. Thrivent Financial for Lutherans increased its holdings in Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker's stock worth $30,931,000 after buying an additional 48,286 shares during the last quarter. Aureus Asset Management LLC raised its position in Abbott Laboratories by 25.0% during the first quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker's stock valued at $34,078,000 after acquiring an additional 66,422 shares in the last quarter. Finally, BXM Wealth LLC lifted its stake in Abbott Laboratories by 612.7% in the fourth quarter. BXM Wealth LLC now owns 28,772 shares of the healthcare product maker's stock valued at $3,605,000 after acquiring an additional 24,735 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories Trading Up 0.4%

Shares of ABT stock opened at $105.99 on Friday. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company has a market cap of $183.40 billion, a PE ratio of 34.30, a price-to-earnings-growth ratio of 2.04 and a beta of 0.61. The company has a quick ratio of 1.01, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The business's 50 day moving average is $93.45 and its two-hundred day moving average is $100.62.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. Abbott Laboratories's quarterly revenue was up 13.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. Abbott Laboratories's payout ratio is presently 81.55%.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Raised earnings estimate: Erste Group Bank increased its FY2026 EPS forecast for Abbott to $5.52 from $5.47, matching the broader consensus estimate. The revision reinforces expectations for continued earnings growth. Erste Group raises Abbott earnings estimate
• Positive Sentiment: Recent results remain supportive: Abbott’s latest quarterly report exceeded analyst expectations for both earnings and revenue, with revenue rising 13% year over year. Management also provided FY2026 EPS guidance of $5.45 to $5.60, supporting the positive earnings narrative.
• Positive Sentiment: Strategic diversification and income appeal: A comparison with Johnson & Johnson highlighted Abbott’s broad exposure to medical devices and diagnostics, strengthened by the Exact Sciences acquisition. Separately, analysts continue to identify ABT as an attractive Dividend Aristocrat for investors seeking recurring cash income. Abbott versus Johnson and Johnson comparison
• Neutral Sentiment: Healthcare-sector momentum: Strong performances from AbbVie and Guardant Health indicate continued investor interest in healthcare and diagnostics, but these companies’ results do not directly change Abbott’s fundamentals.
• Negative Sentiment: Valuation pressure: UBS lowered its expectations for Abbott’s stock price, potentially limiting upside and weighing on sentiment after the recent recovery. UBS lowers Abbott stock price expectations

Analyst Upgrades and Downgrades

Several research firms have commented on ABT. Sanford C. Bernstein decreased their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an "outperform" rating for the company in a research report on Friday, April 17th. Argus reduced their price objective on shares of Abbott Laboratories from $140.00 to $125.00 and set a "buy" rating for the company in a research note on Tuesday, April 21st. Weiss Ratings cut shares of Abbott Laboratories from a "hold (c-)" rating to a "sell (d+)" rating in a report on Thursday, July 23rd. Mizuho lowered their target price on shares of Abbott Laboratories from $125.00 to $115.00 and set a "neutral" rating on the stock in a research report on Friday, April 17th. Finally, The Goldman Sachs Group cut their target price on Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating on the stock in a report on Wednesday, May 27th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $118.17.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.